Island Pharmaceuticals had been awarded a key patent in the United States for ISLA-101, its key asset in the development for antiviral therapies with a key focus being mosquito borne viral diseases. The patent allows for protection and further development of these therapies in the US – a key target market for Island Pharmaceuticals. Mosquito borne viruses, such as dengue, Zika and others represent major unmet medical needs throughout the world. About 3 billion people – or 40% of the world’s population – live in areas with a risk of dengue and approximately 390 million people are infected per year. Additionally, although these diseases are traditionally associated with developing countries, due to global warming, mosquitoes carrying these diseases are travelling farther into areas such as the US and Australia. Aurea lead Series C equity raise and is a reference investor in Island Pharmaceuticals. For the complete press release, please click on the links below.
https://www.islandpharmaceuticals.com/site/PDF/c903ec8c-f1ce-496b-9adb-0870b782637d/IslandPharmaceuticalsgrantedkeyUnitedStatespatent https://www.islandpharmaceuticals.com/
Comments